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TFIIB recognizes DNA sequence-specific motifs that can flank the TATA elements of the promoters of
protein-encoding genes. The TFIIB recognition elements (BREu and BREd) can have positive or negative effects
on transcription in a promoter context-dependent manner. Here we show that the BREs direct the selective
recruitment of TFIIA and NC2 to the promoter. We find that TFIIA preferentially associates with BRE-
containing promoters while NC2 is recruited to promoters that lack consensus BREs. The functional relevance
of the BRE-dependent recruitment of TFIIA and NC2 was determined by small interfering RNA-mediated
knockdown of TFIIA and NC2, both of which elicited BRE-dependent effects on transcription. Our results
confirm the established functional reciprocity of TFIIA and NC2. However, our findings show that TFIIA
assembly at BRE-containing promoters results in reduced transcriptional activity, while NC2 acts as a positive
factor at promoters that lack functional BREs. Taken together, our results provide a basis for the selective
recruitment of TFIIA and NC2 to the promoter and give new insights into the functional relationship between
core promoter elements and general transcription factor activity.
Transcription of a gene by RNA polymerase II requires the
assembly of the general transcription factors at the promoter to
form a preinitiation complex (PIC). The eukaryotic core pro-
moter contains DNA sequence elements that direct the assem-
bly of the general transcription factors and provide a platform
for the recruitment of the PIC (4, 29, 53, 59). These elements
include the TATA box, initiator, downstream promoter ele-
ment (DPE), downstream core element, and motif 10 element
(41). In addition, the general transcription factor TFIIB can
recognize two distinct elements within the core promoter that
flank the TATA box: the upstream and the downstream TFIIB
recognition elements (BREu and BREd) (reviewed in refer-
ence 17).
Interaction with BREu is mediated by a helix-turn-helix
within the second direct repeat of TFIIB, and interaction with
BREd is mediated through a recognition loop within the first
direct repeat (16, 39, 60). These interactions serve to increase
the affinity of TFIIB in forming a complex with TATA-binding
protein (TBP) at the promoter. Each of the BREs is potentially
present in up to 30% of human TATA-containing promoters,
but the extent of their functional influence remains to be de-
termined (16, 25, 39). BREs can also function at TATA-less
promoters, but their identification in this context is less reliable
and thus their potential genome-wide prevalence is difficult to
estimate. The function of BREs in transcription appears to be
complex. The BREs can act as both positive and negative
elements (8, 16, 19, 39). Moreover, activator proteins can mod-
ulate the interaction between TFIIB and BREu (19).
At the adenovirus major late (AdML) promoter the BREs
act as negative elements (8, 16, 19). The reason for this is not
known, but candidates for involvement include the general
transcription repressors Mot1 and NC2. Mot1 acts to prevent
the interaction between TBP and the TATA box, but NC2 can
assemble with TBP at the promoter and precludes the assem-
bly of TFIIB or TFIIA, thus preventing formation of the PIC
(reviewed in references 50 and 59). NC2 is composed of two
subunits,  and , also known as Dr1 and DRAP, respectively
(27, 33, 34, 36, 48). TFIIA can compete with NC2 for associ-
ation with TBP at the promoter, and this mutually exclusive
assembly is underpinned by genetic studies of Saccharomyces
cerevisiae that show a direct relationship between TFIIA and
NC2 (64). In addition, assembly of NC2 with TBP at the TATA
box can mobilize the complex to translocate along the DNA
(52). NC2 also inhibits transcription by RNA polymerase III
(pol III), but not by pol I (35, 62). A few studies over the last
few years have unhinged the apparently established reciprocity
between NC2 and TFIIA. Several reports have suggested a
positive function for NC2 (5, 7, 11, 22, 63). In addition, the
transcription-regulatory properties of NC2 exhibit core pro-
moter-specific activities (1, 45, 63). How the positive activities
of NC2 reconcile with the reciprocal nature of NC2 and TFIIA
in directing transcription has not been determined.
TFIIA is composed of three subunits, , , and  (reviewed
in reference 30), with the  and  subunits derived from a
single gene (15, 43, 49, 57, 66). Although TFIIA was originally
characterized as a general transcription factor, many in vitro
transcription systems do not require TFIIA, and TFIIA is
perhaps better described as a general cofactor that enhances
transcription activation. Indeed, transcriptional activator pro-
teins can stimulate the assembly of a TFIIA-TFIID complex at
the promoter (9, 37, 40, 42, 44, 55).
In this study we have analyzed the role of the BREs in the
negative regulation of the AdML promoter in living cells. We
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find that the BREs direct the mutually exclusive assembly of
TFIIA and NC2. Moreover, TFIIA and NC2 correlate with low
and high promoter activities, respectively. Use of small inter-
fering RNA (siRNA) to specifically deplete TFIIA and NC2 in
living cells confirms a positive role for NC2 in transcription
and, surprisingly, a transcriptional dampening role for TFIIA.
We provide evidence that this involves overlapping recognition
of the core promoter by TFIIA with the BREs.
MATERIALS AND METHODS
Plasmids, site-directed mutagenesis, and cloning. G5ML containing nucleo-
tides 50 to 22 from the AdML promoter downstream of five GAL4 DNA-
binding sites and the plasmid driving expression of GAL4 region II activation
domain linked to the GAL4 DNA-binding domain have been described before
(19). All AdML promoter derivatives were produced with the QuikChange kit
(Stratagene). G5ML and derivatives were subcloned into the reporter vector
pGL3 basic (Promega).
Cell lines. Human embryonic kidney 293T cells were cultured in complete
medium (Sigma) as described previously (6, 47). The HEK293 stable cell lines
were generated using the Flp-In system (Invitrogen). Briefly, the system uses an
engineered 293 cell line derivative that contains a single copy of the Flp recom-
binase targeting site (FRT) under the control of a zeocin selection marker. The
AdML promoter (wild type or AdMLmBREud derivative) linked to luciferase
was cloned into pcDNA5/FRT, replacing the cytomegalovirus promoter within
the plasmid. The resulting plasmids (pcDNA5/FRT-AdML-luc and pcDNA5/
FRT-AdMLmBRE-luc) were transfected into the zeocin-resistant HEK 293 cells
along with the plasmid pOG44 (Invitrogen), which expresses the recombinase.
Stable cell lines were obtained from single colonies through selection with
hygromycin b.
Transfection, luciferase assays, and immunoblotting. Human embryonic kid-
ney 293T cells were cultured in complete medium (Sigma) as described previ-
ously (6, 47). The HEK 293T cells were transfected with Lipofectamine 2000
transfection reagent (Invitrogen). Cells were harvested at 48 h posttransfection,
and the luciferase activity was determined by using the luciferase and -galac-
tosidase dual-light detection system (Applied Biosystems) as described previ-
ously (28). Meanwhile, 20 l of cell lysate for each transfection was used for
immunoblotting, where all primary antibodies for NC2 (ab50783), TFIIA/
(ab28176), TFIIA (ab37846), TFIIB (ab12094), the pol II C-terminal domain
(ab24758), TBP (ab818), and Mot1 (ab5268) were purchased from Abcam.
Secondary antibodies were from Jackson ImmunoResearch. Detection in West-
ern blots was performed by enhanced chemiluminescence (GE Healthcare).
ChIP assays. Chromatin immunoprecipitation (ChIP) assays were performed
according to the published method (54) with modifications. Briefly, cells were
cross-linked with 1% formaldehyde–phosphate-buffered saline for 10 min at
room temperature and quenched by the addition of glycine to a final concentra-
tion of 250 mM. The cells were washed twice with cold phosphate-buffered saline
and harvested. For the ChIP assays of the AdML promoter and derivatives, the
cells were Dounce homogenized. Cell lysates were then transferred to micro-
tubes, and the nuclei were collected by brief centrifugation and then resuspended
in lysis buffer (50 mM Tris-Cl, pH 8.0, 10 mM EDTA, 1% sodium dodecyl
sulfate). Samples were then sonicated for 10 min at high power with a Diagenode
sonicator. After sonication, the samples were centrifuged in a benchtop micro-
centrifuge at 4°C, and the supernatants were diluted with ChIP dilution buffer
(0.01% sodium dodecyl sulfate, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM
Tris-Cl, pH 8.0, 167 mM NaCl). For immunoprecipitation, the samples were
precleared using preblocked protein G-Sepharose (Sigma) with 1 mg/ml bovine
serum albumin and 0.1 mg/ml salmon sperm DNA. Two micrograms of each
antibody was added to the samples, and samples were incubated overnight at 4°C,
followed by the addition of 20 l preblocked protein G-Sepharose to the samples
and incubation for 1 h at room temperature. The remainder of the procedure was
followed according to the method described previously (54) except that the
washing step was prolonged to 0.5 to 1 h for each wash and that the DNA was
purified with a Qiagen DNA purification kit. For endogenous promoter ChIP
assays, the cells were directly lysed in nucleus lysis buffer after harvesting, fol-
lowed by sonication. All other steps were the same as those used for the AdML
promoter ChIP assays. The primers used in the PCRs were as follows: AdML
forward, 5-CTAGCAAAATAGGCTGTCCC-3; reverse, 5-TCCAGCGGATA
GAATGGC-3; Bcl2 forward, 5-TTCCTGCATCTCATGCCAAG-3; reverse,
5-GGATGTACTTCATCACTATCTC-3; insulin-like growth factor II (IGFII)
forward, 5-CTCTTGGCTCGGGTTGCGG-3; reverse, 5-GCAGGCGTGGG
CCAGGAGG-3.
The primers used for real time PCR were as follows: forward, 5-GAGGAT
CCGTGTTCCTGAAG-3; reverse, 5-GAGTCAGTGAGCGAGGAA-3. Real
time PCR was performed with CYBR green master mix (Eurogentec) and a
Chromo 4 thermal cycler machine (MJ Research). The program used for PCR
was 94°C for 45 s, 60°C for 30 s, and 72°C for 30 s for a total of 35 to 40 cycles.
The enrichment of target DNA (relative occupancy) is expressed as the ratio of
the amount of promoter DNA bound to the protein of interest compared to
nonpromoter DNA. The input DNA was derived from 1/10 of the volume of
sample used for immunoprecipitation of the target protein. All experiments were
performed at least in triplicate.
siRNA knockdown, RNA isolation, and RT-PCR. Double-stranded siRNA
oligonucleotides for TFIIA, TFIIA, NC2, and NC2 were purchased from
Eurofins Biotech. The second TFIIA siRNA (2) was obtained from Santa
Cruz Biotechnology. Sequences of the siRNAs were as follows: NC2, 5-AGA
GGAACGAAGAAGAUUACTT-3; NC2, 5-UUGGAGAGCUAAGUAAG
UATT-3; TFIIA, 5-GUACUGAUGGAACUAAAAATT-3; TFIIA, 5-A
CAGAUCACCCCCCAACUUTT-3. siRNAs (10 pmol) were transfected with
Lipofectamine 2000 (Invitrogen) either alone or in combination with plasmid
DNA. Forty-eight hours after transfection, cells were harvested and used for
either luciferase assays, Western blotting, or the preparation of RNA. Total
RNA was prepared with the RNeasy minikit (Qiagen). For reverse transcription-
PCR (RT-PCR), cDNAs were synthesized from 3 g of total RNA for each
sample with the Access reverse transcription kit (Promega) and subjected to
PCR with primers to amplify the RNA. Primers used for RT-PCR were as
follows: IGFII forward, 5-GAGTGCTGTTTCCGCAGCTGTG-3; reverse, 5-
CTGAACGCCTCGAGCTCCTTG-3; P21 forward, 5-GAACTTCGACTTTG
TCACCG-3; reverse, 5-GGTAGAAATCTGTCATGCTG-3; Egr1 forward,
5-CGCAAGAGGCATACCAAGATCC-3; reverse, 5-CAGCTGAGGAAGG
GAAGCTG-3; BCL2 forward, 5-GTGGTGGAGGAGCTCTTCAG-3; re-
verse, 5-GCAGAGTCTTCAGAGACAGCC-3; 18S forward, 5-GTAACCCG
TTGAACCCCATT-3; reverse, 5-CCATCCAATCGGTAGTAGCG-3.
Proteins and band shift. Promoter DNA for wild-type AdML and AdML
derivatives was labeled with [-32P]dATP (GE Healthcare). Purified native
TFIIA was obtained from Protein One Inc. NC2 protein was prepared from
Escherichia coli BL21 coexpressing NC2 and NC2 from a bicistronic plasmid
(described in reference 44). Ni-nitrilotriacetic acid–agarose chromatography was
used to purify the NC2 via a His tag at the N terminus of NC2. Recombinant
human TBP and TFIIB were purified as described before (16, 26). Band shift
assays were performed as described previously (26).
RESULTS
The AdML promoter contains both a BREu and BREd that
flank the TATA element (Fig. 1A). Based on previous func-
tional data we generated mutant derivatives of this promoter
that lack a functional BREu (AdMLmBREu), BREd (AdMLm-
BREd), both BREs (AdMLmBREud), or the TATA element
(AdMLmTATA) (16, 19, 39). The promoter derivatives, driv-
ing luciferase expression and controlled by five GAL4 DNA-
binding sites, were transfected into human embryonic kidney
293T cells along with a plasmid driving expression of GAL4-
RII (GAL4 residues 1 to 147, linked to the region II activation
domain of GAL4) and a -galactosidase internal control. Cells
were harvested 48 h later, and luciferase activity was measured
and presented graphically in Fig. 1B. Consistent with our pre-
vious results and those of others, mutation of either BREu or
BREd caused an increase in promoter activity (8, 16, 19).
Mutation of both BREs within the AdML caused a further
increase in promoter activity, and mutation of the TATA ele-
ment resulted in a significant reduction in promoter activity.
Thus, the BREs within the AdML promoter act as negative
elements either alone or in combination.
To determine the mechanisms that underlie the negative
function of the BREs within the AdML promoter, we next
assessed the pattern of assembly of key general transcription
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factors at the AdML promoter derivatives in living cells. The
AdML promoter derivatives were transfected as described
above, and then ChIP was performed with the antibodies
indicated in Fig. 1C. TBP assembled at the promoters in a
BRE-independent manner but showed a significant reduc-
tion in assembly at the AdMLmTATA derivative (Fig. 1C,
left). TFIIB and pol II assembled at the promoter derivatives
to levels that reflect their transcriptional potency, exhibiting a
greater level of assembly at the AdML promoter derivatives
with defective BREs (Fig. 1C, left). NC2 also showed an
increase in assembly at the AdML promoters with mutant
BREs (Fig. 1C, right), as did NC2 (see Fig. S1 in the supple-
mental material). TFIIA showed robust assembly at the wild-
type AdML promoter but lower levels of assembly when either
or both of the BREs were mutated (Fig. 1C, right). Taken
together, these data show a strong correlation between the
BREs and TFIIA/NC2 assembly. Specifically, the presence of
the BREs within the AdML promoter enhances TFIIA assem-
bly, and the converse is observed with NC2 (Fig. 1C, right). It
was unexpected, however, that TFIIA assembly should corre-
late with the repressive function of the BREs while NC2 asso-
ciates with the more active promoter derivatives.
Our results so far provide a correlation between TFIIA and
NC2 assembly and the presence of the BREs. Furthermore,
TFIIA assembly and that of NC2 are associated with low and
high promoter activities, respectively. To assess the functional
relevance of the recruitment events in Fig. 1C, we next deter-
mined the contribution of TFIIA and NC2 to BRE-dependent
transcription at the AdML promoter. 293T cells were trans-
fected with siRNA targeting NC2 along with the AdML de-
rivative promoters, a plasmid driving expression of GAL4-RII,
and a -galactosidase internal control. Forty-eight hours later
cells were harvested, samples were taken for immunoblotting,
and the remainder was used to measure luciferase activity (Fig.
2A). The immunoblot confirmed that NC2 was reduced in
cells that were transfected with the NC2 siRNA. The graph in
Fig. 2A shows luciferase activity of the AdML promoter de-
rivatives in the presence of either control siRNA or NC2
siRNA. At the wild-type AdML promoter NC2 knockdown
did not have a significant effect on promoter activity. However,
FIG. 1. Differential recruitment of TFIIA and NC2 at the AdML promoter is dependent upon the BREs. (A) The promoter sequence of the
wild-type (wt) AdML promoter is shown at top, with the TATA element underlined and BREu and BREd shaded at the bases that match their
consensus sequences. (B) The promoter derivatives in panel A, linked to five GAL4 DNA-binding sites and driving luciferase transcription, were
transfected into embryonic kidney 293T cells along with a vector driving expression of GAL4 activation domain II linked to the GAL4
DNA-binding domain. Forty-eight hours later luciferase activity was measured and normalized to -galactosidase activity and is presented
graphically. Each bar represents three independent experiments with standard deviation. (C) 293T cells were transfected as in panel B and
subjected to ChIP with antibodies against TBP, TFIIB, and pol II (left) and TFIIA/ or NC2 (right). The results are presented as enrichment
of specific promoter DNA over nonpromoter DNA in the immunoprecipitate. Each bar represents at least three independent experiments with
standard deviation. A gel-based version of these data, including the analysis of additional factors, is shown in Fig. S1 in the supplemental material.
IgG, immunoglobulin G.
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knockdown of NC2 caused significant reductions in the ac-
tivities of the AdML promoter derivatives in which the BREs
were individually or both mutated (2.2-, 2.7-, and 3-fold). The
mutant TATA AdML derivative also showed a reduction in
activity in the presence of NC2 siRNA (1.9-fold). Taken
together the data show that NC2 does not play a crucial role
in transcription of the wild-type AdML promoter but has a
positive role when either or both of the BREs are mutated. We
next assessed the effect of an siRNA directed against NC2 in
the same way (Fig. 2B). As we observed with NC2, knock-
down of NC2 by siRNA had a negligible effect on the wild-
type AdML promoter but significantly reduced the activities of
FIG. 2. NC2 acts as a positive transcription factor when the BREs in the AdML promoter are rendered nonfunctional. (A) 293T cells were
transfected as for Fig. 1B except that either control siRNA or siRNA targeting NC2 was included. Forty-eight hours later cells were harvested
and used to monitor luciferase activity and also for Western blotting with anti-NC2 antibodies or, as a control, anti--tubulin antibodies. Note
that the immunoblot analysis concerns the whole cell population and therefore underestimates the extent of NC2 knockdown. The graph shows
the relative luciferase activity of the AdML promoter derivatives in the presence of control (Ctrl) or NC2 siRNA. The numbers above the bars
indicate the changes in activity that are caused by the NC2 siRNA. wt, wild type. (B) Same as panel A, except that siRNA targeting NC2 was
used. (C) Same as panel A, except that a different siRNA targeting NC2, NC2 (2) siRNA was used and only the wild-type AdML and
AdMLmBREud reporters were tested. Each bar represents three independent experiments with standard deviation.
1392 DENG ET AL. MOL. CELL. BIOL.
 o
n
 February 25, 2014 by Cardiff Univ
http://m
cb.asm
.org/
D
ow
nloaded from
 
the AdML derivative promoters that contain the mutant BREs
(1.5-, 1.6-, and 1.9-fold). Western blotting confirmed that the
expression of NC2 was reduced by the siRNA. A second
siRNA targeting NC2, NC2 (2) siRNA, produced compa-
rable results (Fig. 2C). Taken together, the data show that
ablation of either NC2 or NC2 does not significantly affect
transcription at the wild-type AdML promoter. However,
when either or both of the BREs are ablated, NC2 and NC2
have a positive effect on transcription. These data are consis-
tent with our ChIP analysis (Fig. 1C); NC2 or NC2 ablation
elicits the greatest effect on the same AdML derivatives that
also show greater NC2 recruitment in vivo.
FIG. 3. (A) BRE-dependent function for TFIIA at the AdML promoter. 293T cells were transfected as for Fig. 1B except that either control
siRNA or siRNA targeting TFIIA/ was included. Forty-eight hours later cells were harvested and used to monitor luciferase activity and also
for Western blotting with anti-TFIIA/ antibodies or, as a control, anti--tubulin antibodies. Note that the immunoblot analysis concerns the
whole cell population and therefore underestimates the extent of TFIIA/ knockdown. The graph shows the relative luciferase activity of the
AdML promoter derivatives in the presence of control (Ctrl) or TFIIA/ siRNA. The numbers above the bars indicate the changes in activity
that are caused by the TFIIA/ siRNA. The difference in changes between the wild-type (wt) AdML reporter and AdMLmBREud was subjected
to Student’s t test and was found to be significant (P  0.05). (B) Same as panel A, except that a different siRNA targeting TFIIA/, TFIIA/
(2) siRNA, was used and only the wild-type AdML and AdMLmBREud reporters were tested. (C) Same as panel A, except that siRNA targeting
TFIIA was used. Each bar represents three independent experiments with standard deviation.
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We next used siRNA to target the  and  subunits of TFIIA
and monitored the activity of the AdML promoter derivatives
as described above (Fig. 3A). Western blotting confirmed that
TFIIA and particularly TFIIA expression was knocked
down by the siRNA. At the wild-type AdML promoter, knock-
down of TFIIA and TFIIA (TFIIA/) caused a 2.1-fold
increase in promoter activity. At the AdML derivatives har-
boring individual or combined mutant BREs, however, the
effect of TFIIA/ siRNA was reduced (1.4- to 1.5-fold). The
TFIIA/ siRNA also had little effect on the AdML promoter
derivative with a defective TATA element. A second siRNA
targeting TFIIA/, TFIIA/ (2) siRNA, produced compa-
rable results (Fig. 3B). siRNA targeting TFIIA also elicited a
positive effect on transcription at the wild-type AdML pro-
moter (2-fold) but had a reduced effect on transcription at the
AdML derivatives with individual (1.3- and 1.7-fold) or com-
bined (1.1-fold) defective BREs (Fig. 3C). Also, as observed
with the TFIIA/ siRNA, the TFIIA siRNA did not signif-
icantly affect transcription at the AdML promoter derivative
with a defective TATA element. Again, these results are con-
sistent with the ChIP data of Fig. 1C; TFIIA recruitment is
greatest at the wild-type AdML promoter, at which TFIIA
ablation by siRNA also has the greatest effect. Moreover, con-
sistent with the observation that the extent of TFIIA recruit-
ment correlates with the least-active TATA-containing pro-
moter, TFIIA knockdown has a positive effect on transcription
at this same promoter. These results suggest that TFIIA has a
dampening effect on transcription at the AdML promoter that
is dependent upon the presence of the BREs.
Our studies so far have used transiently transfected AdML
promoter derivatives. We were interested in determining if the
effects that we observed would also occur at AdML promoter
derivatives that were stably integrated within the genome. For
this analysis we used the Flp-In system, which employs a 293
cell line derivative containing a single FRT within the genome.
Plasmids containing the wild-type AdML promoter or mutant
BREud derivative linked to luciferase and flanked by FRT
sequences were generated and used to create 293 cell line
derivatives that contain a single copy of the AdML promoter
(or BREud mutant derivative) integrated at a defined location.
Three independent cell lines each for the wild-type AdML
promoter or BREud mutant were derived, and the activities of
the promoters were compared by luciferase assay (Fig. 4A).
Consistent with our transient transfection data, all three cell
line derivatives containing the AdMLmBREud promoter ex-
hibited significantly greater luciferase activity than the cell
lines generated with the wild-type AdML promoter.
We next performed ChIP by quantitative PCR with the
stable AdML and AdMLmBREud cell lines to assess the oc-
cupancy of the stably integrated promoters by TFIIA/ and
NC2 (Fig. 4B). The results are in agreement with our ChIP
analysis of the episomal wild-type AdML promoter and
AdMLmBREud derivative (Fig. 1C). Specifically, TFIIA pref-
erentially associates with the integrated wild-type AdML pro-
moter and NC2 preferentially associates with the integrated
AdMLmBREud derivative. Moreover, as observed with ChIP
of the episomal AdML derivatives, TFIIB and pol II showed
significantly higher levels of occupancy at the more active
AdMLmBREud promoter than at the wild-type AdML pro-
moter. We further analyzed the stable cell lines using siRNA to
target either TFIIA/ or NC2 expression (Fig. 4C). As be-
fore, the wild-type AdML promoter was more sensitive to
TFIIA depletion, showing enhanced transcriptional function in
response to the TFIIA/ siRNA. Conversely, the AdMLm-
BREud derivative was more sensitive to NC2 depletion, show-
ing reduced transcription function in response to NC2
siRNA. Thus, the suppressive effect of TFIIA and positive
effect of NC2 on BRE-dependent transcription are equivalent
at both episomal and stably integrated AdML promoter deriv-
atives.
We next sought to confirm and extend our data using a series
of natural promoters that contain different combinations of
and levels of conformity to the consensus sequences of the
BREs (Fig. 5A). Plasmids containing these promoters driving
luciferase expression were transfected into 293T cells along
with either NC2 or NC2 siRNA. Forty-eight hours later the
cells were harvested. NC2 and NC2 expression was moni-
tored by Western blotting, and luciferase activity was measured
and is presented graphically (Fig. 5B). To aid interpretation,
the effects of each of the NC2 siRNAs are presented relative to
that of the control siRNA at each promoter, which has been set
at an arbitrary value of 10. siRNA-mediated knockdown of
NC2 caused a decrease in activity of the BCL2, p21, podoca-
lyxin, and Egr1 promoters. At the BCL2 and Egr1 promoters,
however, we note that the NC2 siRNA was consistently less
effective than the NC2 siRNA. The IGFII promoter was
refractory to both the NC2 and NC2 siRNAs; significantly,
this promoter contains the sequence most similar to the con-
sensus BRE sequences of all the promoters tested. Indeed, we
have reported previously that the IGFII promoter BREu is
contacted by TFIIB (20). In addition, band shift analysis con-
firmed that the BRE sequences of the IGFII promoter pro-
vided greater functionality in TFIIB recognition than the cor-
responding sequences of the BCL2 promoter (see Fig. S2 in
the supplemental material).
We next tested the effects of TFIIA ablation on the natural
promoters (Fig. 5C). All of the promoters elicited a positive
effect in response to TFIIA/ and TFIIA siRNA. However,
the greatest effect was observed with the IGFII promoter while
the smallest effect was observed with the BCL2 promoter.
Although the effects of NC2 and TFIIA siRNA at the natural
promoters are more complex than those observed with the
AdML mutant derivatives (in which targeted mutations of the
BREs were performed based on previous functional data), it is
clear that the IGFII promoter, which contains the sequence
most similar to the consensus BRE sequences, is least depen-
dent on NC2 for activity and is suppressed to the greatest
degree by TFIIA (see summary diagram in Fig. 5D). All the
other promoters show some degree of dependence on NC2 for
full activity, while TFIIA is least inhibitory at the BCL2 pro-
moter.
We next analyzed the effect of TFIIA and NC2 siRNA on
the expression of the endogenous genes that correspond to the
reporter plasmids used in Fig. 5. 293T cells were transfected
with control, NC2, NC2, TFIIA/, or TFIIA siRNA, and
48 h later the cells were harvested and used to prepare whole-
cell extracts or total RNA. RT-PCR was used to analyze the
expression levels of IGFII, p21, Egr1, BCL2, and, as a control,
pol I-transcribed 18S rRNA (Fig. 6A). Western blots of the
associated whole-cell extracts with antibodies against several
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general transcription factors are shown. The endogenous
podocalyxin gene is not expressed in 293 cells. Both TFIIA/
and TFIIA siRNA caused an increase in Egr1 and IGFII
mRNA. Significantly, the Egr1 and IGFII promoters were
found to be the most responsive to TFIIA siRNA when the
reporters were tested (Fig. 5C). The NC2 siRNA caused a
reduction in the abundance of BCL2, Egr1, and p21 mRNA
but had no effect on the level of IGFII mRNA. NC2 siRNA
also had a negative effect on BCL2 and p21 promoter activity,
but not Egr1 or IGFII promoter activity. Taken together, the
results of the analysis of the endogenous genes confirm that
IGFII is actively suppressed by TFIIA but is not dependent
upon NC2 for activity. Conversely, the BCL2 promoter is de-
pendent on NC2 for full activity but is not suppressed by
TFIIA.
We next performed ChIP analysis on the endogenous BCL2
and IGFII core promoters to assess the relative assembly of the
general transcription factors, including TFIIA and NC2 (Fig.
6B). The BCL2 core promoter showed robust assembly of
NC2 and NC2, but not TFIIA, consistent with its poor BRE
sequences and also the effects of the NC2 and TFIIA siRNAs.
In addition, the IGFII promoter showed robust TFIIA assem-
bly but low levels of NC2 and NC2 assembly, consistent with
the strong BRE consensus sequences and the effects of the
NC2 and TFIIA siRNAs.
Our data so far suggest that the presence of BREs within a
promoter results in the preferred assembly of TFIIA instead of
NC2 at the promoter and elicits a dampening effect on tran-
scription. In the absence of BREs (or with BREs having low
similarity to the high-affinity sequences), NC2 preferentially
assembles over TFIIA and elicits a positive effect on transcrip-
tion. We were therefore interested to determine directly the
FIG. 4. Analysis of TFIIA and NC2 function at stably integrated AdML derivatives. (A) Three independent cell lines were generated for both
the wild-type (wt) AdML promoter and mutant BREud derivative using the Flp-In system. Luciferase activity for each of the cell lines was assessed
and is presented graphically as the mean average of three independent experiments with standard deviation. (B) The wild-type AdML and
AdMLmBREud stable cell lines were used for ChIP analysis to assess the promoter occupancy of TFIIA/ and NC2 (left) and TFIIB and pol
II (right). ChIP was performed as for Fig. 1C except that detection was by real-time PCR, and the results are presented graphically. Immuno-
globulin G (IgG) is used as a negative control antibody in the reaction. The results are presented as enrichment of precipitation of specific
promoter DNA over nonpromoter DNA. Each bar represents at least three independent experiments with standard deviation. (C) The wild-type
AdML and AdMLmBREud stable cell lines were transfected with either TFIIA/, NC2, or a control siRNA. Luciferase activity was assessed
and is presented graphically as the mean of three independent experiments with standard deviation. The difference in changes between the
wild-type AdML and AdMLmBREud was subjected to Student’s t test and found to be significant (P 0.05). At the right is an immunoblot showing
successful depletion of TFIIA and NC2 expression by the siRNA.
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FIG. 5. Natural promoters exhibit BRE-dependent TFIIA and NC2 function. (A) The core promoter regions of five natural promoters are shown, with the
TATA element underlined. The BREu and BREd regions are shown, and bases that conform to the consensus sequences are shaded. (B) The five promoters
indicated, linked to luciferase, were transfected into 293T cells along with control (Ctrl) siRNA, NC2 siRNA, or NC2 siRNA. Forty-eight hours later the cells
were harvested and used to monitor luciferase activity and also for Western blotting with anti-NC2 antibodies, anti NC2 antibodies, or, as a control,
anti--tubulin antibodies. Luciferase activity is shown graphically, and each bar represents three independent experiments with standard deviation. To aid
comparison of the effects of the siRNAs on the different promoters, the activity of each promoter in the presence of control siRNA was set to 10. (C) The five
promoters indicated, linked to luciferase, were transfected into 293T cells as for panel B, but along with control siRNA, TFIIA/ siRNA, or TFIIA siRNA.
Forty-eight hours later the cells were harvested and used to monitor luciferase activity and also for Western blotting with anti-TFIIA/ antibodies, anti TFIIA
antibodies, or, as a control, anti--tubulin antibodies. Luciferase activity is shown graphically, and each bar represents three independent experiments with
standard deviation. To aid comparison of the effects of the siRNAs on the different promoters, the activity of each promoter in the presence of control siRNA
was set to 1. (D) Summary of the effects of NC2 and TFIIA siRNAs on the activities of the natural promoters. For each promoter the BREu and BREd match
to the consensus (out of 7 bases) is shown. The transcriptional effects of the siRNAs are denoted by upward (stimulation)- and downward (repression)-pointing
arrowheads. The number of arrowheads in each case is proportional to the change in luciferase activity. The BCL2 and IGFII promoters are discussed further
in the text.
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effect of the BREs on the affinity of TFIIA and NC2 for
promoter-bound TBP in the absence of other factors. The
wild-type AdML promoter and mutant BRE derivative
AdMLmBREud were radiolabeled and incubated with recom-
binant human TBP along with TFIIA, and the complexes were
resolved by native electrophoresis (Fig. 7A). TFIIA-TBP-pro-
moter complexes formed more avidly with the wild-type AdML
promoter than with the AdML promoter derivative in which
the BREs had been rendered nonfunctional (AdMLmBREud).
We next performed a band shift reaction with purified recom-
binant NC2 and TBP (Fig. 7B). The NC2-TBP-AdML com-
plexes resolved as two forms; thus, the presence of NC2 within
the complexes was verified by supershifting the complex with
anti-NC2 antibodies. Significantly, NC2-TBP-promoter com-
plexes did not show any dependence on the BRE for their
formation. Assembly of either TFIIA or NC2 at the AdML
promoter required the presence of TBP (Fig. 7C). In addition,
consistent with previous studies, TFIIB shows reduced assem-
bly at the AdMLmBREud promoter derivative compared with
that at the wild-type AdML promoter (Fig. 7D). Thus, the
BREs drive formation of either TFIIA-TBP-promoter com-
plexes or TFIIB-TBP-promoter complexes, but not NC2-TBP-
promoter complexes.
DISCUSSION
The BREs can elicit either positive or negative effects on
transcription. While the positive effect can be explained by the
increased affinity of TFIIB for the promoter, the molecular
basis for the negative effect is unclear. In this study we have
shown that the presence of BREs in the AdML promoter
determines the relative assembly of TFIIA and NC2. Surpris-
ingly, however, TFIIA recruitment correlated with reduced
promoter activity while NC2 recruitment correlated with high
promoter activity. Treatment of cells with siRNA to reduce
endogenous TFIIA and NC2 levels revealed that TFIIA sup-
presses transcription at the AdML promoter in a BRE-specific
manner and that NC2 provides a positive transcriptional func-
tion in the absence of BREs. In vitro studies confirmed that the
BREs enhance the formation of a TFIIA-TBP-promoter com-
plex.
A positive role for NC2 in transcription has been observed
before (5, 7, 11, 22, 63). How NC2 can act as a positive factor
is not yet known, but it is possible that it acts by stabilizing or
“priming” TFIID at the promoter, before release and replace-
ment by factors (e.g., TFIIB) that can drive PIC assembly
forward. Such a mechanism has been described before for the
positive activities of Mot1 (14, 23, 24, 32). Indeed, active tran-
scription complexes that contain Mot1 also contain TFIIB and
pol II, but not TFIIA (24). We also note that RNA interfer-
ence (RNAi)-mediated knockdown of NC2 frequently elic-
ited a less pronounced effect on transcription than RNAi-
mediated knockdown of NC2, particularly with the natural
promoters. This is consistent with previous reports of poten-
tially independent activities for NC2 or NC2 (13, 33, 65),
although our ChIP analysis suggests that both components
generally assemble at the promoter together.
Recent genome-wide ChIP-on-chip experiments have found
that NC2 associates with 25% of promoters in the genome and
generally correlates with high expression, reaffirming a positive
function for NC2 in transcription (1). Furthermore, this same
study showed that association of NC2 with promoters shows an
inverse correlation with the BRE core promoter element. Our
results are entirely consistent with these findings and further
suggest that this inverse correlation between the BRE and
NC2 promoter occupancy arises from the binding of TFIIA to
BRE-like sequences. Thus, our data raise the prospect of
FIG. 6. Endogenous promoters exhibit a BRE-dependent tran-
scriptional requirement for and recruitment of TFIIA and NC2.
(A) 293T cells were transfected with either a control (Ctrl) siRNA or
the siRNAs indicated at the top. Forty-eight hours later the cells were
harvested and both total RNA and whole-cell protein lysates were
prepared. BCL2, Egr1, p21, and IGFII mRNAs were detected by
RT-PCR, and assurance that the reactions were performed in the
linear range was determined by a dilution profile of the RNA sample
obtained from cells treated with control siRNA. Below, Western blots
of the whole-cell lysates with the antibodies indicated at the right are
shown. (B) 293T cells were subjected to ChIP with the antibodies
indicated at the top. The core promoter regions of the BCL2 and
IGFII genes were amplified by PCR, and amplification of the 18S
coding region served as a negative control (bottom). Assurance that
the reactions were performed in the linear range was determined by a
dilution profile of the input chromatin prior to PCR. IgG, immuno-
globulin G.
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TFIIA recognition elements that share at least some similarity
to the BREs. Indeed, previous cross-linking studies have
shown that TFIIA contacts the core promoter within both the
BREu and BREd elements, and it is possible that TFIIA might
share overlapping DNA sequence-specific recognition with
TFIIB (12, 38). The crystal structures of yeast TFIIA com-
plexed with TBP at the AdML and CYC promoters revealed
base contact upstream of the TATA element, including contact
with a G 3 nucleotides upstream of the TATA element (3, 21,
58). We note that a G 3 nucleotides upstream of the TATA
element forms a critical part of BREu and was replaced in our
mutant AdML derivatives. In addition, several other residues
in the above structure were in close proximity to the upstream
DNA with potential to form direct contact. The DNA fragment
used in these studies did not extend sufficiently 3 of the TATA
box to encompass the BREd region. Our band shift data,
revealing BRE-dependent enhancement of TFIIA-TBP-pro-
moter complex formation, are therefore consistent with previ-
ous studies and also with our ChIP data.
Our experiments revealed the surprising finding that reduc-
tion of cellular TFIIA enhances transcription at the wild-type
AdML promoter. Moreover, BRE-directed recruitment of
TFIIA at the AdML promoter correlated with reduced pro-
moter activity. A previous study found that a highly pure
TFIIA fraction repressed transcription in vitro at the AdML
promoter, but not at TATA-less promoters (2). Indeed, we
also observed that transcription at the AdML derivative that
lacks a TATA element was not affected by the TFIIA siRNAs.
However, the TATA-less podocalyxin promoter was repressed
by TFIIA, suggesting that the repressive function of TFIIA is
dependent on multiple factors. Indeed, Stargell et al. (56) have
reported core promoter-dependent effects of TFIIA. It will
therefore be important to test the other core promoter se-
quence elements (including the initiator, DPE, downstream
core element, and the motif 10 element) with regard to TFIIA
and NC2 function. Recent work by Hsu et al. (31) employed
RNAi in drosophila cells to assess the role of several general
transcription factors at DPE-containing versus TATA-contain-
ing core promoters. In addition to a positive function for NC2,
they uncovered DPE- and TATA-dependent roles for both
TBP and NC2. In addition, they found that depletion of TFIIA
decreases the activity of a hybrid core promoter containing the
AdML TATA region linked to the Ant P2 or E74B initiator. It
is therefore likely that the core promoter context of the BREs,
FIG. 7. TFIIA assembly at the promoter is BRE dependent. (A) The wild-type AdML promoter and mutant derivative AdMLmBREud were
radiolabeled, and assembly of TBP and TFIIA was monitored by band shift analysis. Where indicated, 50 ng of human TBP (hTBP) was included
in the reaction mixture. Either 50 ng or 250 ng of TFIIA was added. Free probe and TBP-TFIIA-promoter complexes are indicated at the right.
(B) Same as panel A except that 10 ng and 50 ng of purified recombinant NC2 were included instead of TFIIA. Also, where indicated 500 ng of
anti-NC2 antibody was included, and the supershifts are indicated. (C) TFIIA (50 ng) or NC2 (50 ng) was incubated with the radiolabeled AdML
promoter either alone or along with hTBP (50 ng). Complexes were resolved as for panel A. TFIIA-TBP-AdML and NC2-TBP-AdML complexes
and free probe are indicated. (D) Same as panel A except that 50 ng or 250 ng of recombinant human TFIIB was used instead of TFIIA.
1398 DENG ET AL. MOL. CELL. BIOL.
 o
n
 February 25, 2014 by Cardiff Univ
http://m
cb.asm
.org/
D
ow
nloaded from
 
particularly in relation to the initiator, plays a role in deter-
mining the net contribution of TFIIA to transcriptional activ-
ity. Indeed, we have previously reported that the BREs can
exert a positive or negative effect on transcription that is de-
pendent upon the promoter context (16). Moreover, promoter-
specific activities for TFIIA have also been observed in other
studies (10, 36, 40, 42, 46, 56, 61). It should also be noted that,
while yeast TFIIB can also contact BREd sequences (16), con-
tact with BREu does not appear to be conserved (39), suggest-
ing potential differences in the activities of TFIIA with respect
to the BREs.
It is generally assumed that TFIIA and NC2 act in a recip-
rocal manner, with mutually exclusive recruitment to the pro-
moter and effects on transcription. However, as stated previ-
ously, this has been difficult to reconcile with the numerous
reports that NC2 can have a positive effect on transcription.
Our findings provide an explanation that maintains the reci-
procity between TFIIA and NC2, in that TFIIA and NC2 show
mutually exclusive effects on transcription in a BRE-dependent
manner. We suggest that, at promoters with BRE-like se-
quences, TFIIA assembles in preference over NC2. We did not
find BRE-dependent effects in the formation of NC2-TBP-
AdML promoter complexes in vitro (Fig. 7), suggesting that
enhanced assembly of NC2 at non-BRE promoters in vivo is
due to reduced competition from TFIIA-promoter recogni-
tion.
However, it is important to note that the BREu and BREd
consensus sequences are derived from binding site selection
studies and therefore represent the highest-affinity sequences.
Physiologically relevant sequences will likely fall across a broad
spectrum, and it is likely that many BREs might be functional
for TFIIB binding but not act as affinity sites for TFIIA. In
such cases TFIIA and NC2 might elicit more-competitive ef-
fects and therefore respond to ablation of both TFIIA and
NC2 expression. Indeed, this is likely the case at some of the
natural promoters used in this study.
It is well established that TFIIA can stabilize TFIID-pro-
moter contacts, leading to productive PIC formation and tran-
scription. Our data suggest that this pathway of PIC formation
dominates at BRE-containing promoters. An alternative path-
way employs NC2 to stabilize TFIID-promoter complexes. Al-
though both pathways are productive, the NC2 pathway ap-
pears to be more efficient in producing transcriptionally active
complexes. Thus, elimination of TFIIA by siRNA or dimin-
ished TFIIA-promoter recognition (by BRE mutation) leads to
the more efficient NC2 pathway. Our previous work on mam-
malian cells and the work of others on yeast suggested that
TFIIB most likely assembles at the promoter as a complex with
pol II (18, 51). It is possible that ablation of TFIIA by RNAi
might release the BREs for recognition by the TFIIB-pol II
machinery, thereby enhancing transcription. TFIIA and NC2,
by mutually exclusive assembly with TFIID at the promoter,
could therefore provide a commitment step that can either
preclude BRE function or enhance it. Thus, TFIIA might
“shield” the BREs from TFIIB recognition and weaken the
promoter. Conversely, if NC2 “primes” the promoter-TFIID
complex but is subsequently released, this would allow recog-
nition of the BREs by TFIIB, thereby eliciting a positive effect
on transcription. Further studies will shed light on the TFIIB-
TFIIA-NC2 dynamic in living cells.
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